Pre Exposure Prophylaxis News and Research

RSS

Study reveals how state laws affect access to HIV pre-exposure prophylaxis

State laws in the US that require medical doctors (MDs) to determine which medications a nurse practitioner (NP) or physician assistant (PA) can prescribe, and under what conditions, may limit the number of patients who use HIV pre-exposure prophylaxis (PrEP), reports a study in The Journal of the Association of Nurses in AIDS Care.

22 Jan 2022

FDA approval of long-acting injectable drug marks a vital expansion of HIV prevention options

Yesterday the U.S. Food and Drug Administration announced its first approval of a long-acting HIV prevention medication. Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months.

21 Dec 2021

New analysis highlights the global prevalence of HIV among transgender people

A new analysis highlights the prevalence of HIV among transgender individuals worldwide, and shows the need for continued prevention efforts for this population.

1 Dec 2021

World AIDS Day: New Vital Signs report highlights persistent disparities in HIV prevention and care

Despite overall progress in reducing new infections among gay and bisexual men, the HIV epidemic continued and was more severe among Black or African American (hereafter referred to as Black) and Hispanic/Latino gay and bisexual men in the decade leading up to the federal Ending the HIV Epidemic in the U.S. (EHE) initiative, which the U.S. Department of Health and Human Services launched in 2019.

1 Dec 2021

Scientists now close to eliminating mother-baby HIV transmission, says leading researcher

Quarraisha Abdool Karim has spent the past three decades studying HIV and AIDS. She has become one of the world's leading epidemiologists and made major contributions to the global understanding of how HIV affects young women.

24 Nov 2021

RA patients taking glucocorticoids or B-cell therapies may have worse COVID-19 vaccine response

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.

2 Nov 2021

Analysis shows dramatic fall in the number of people living with undiagnosed HIV in England

England is on track to have diagnosed 95% of people living with HIV by 2025, putting it in a strong position to eliminate HIV transmission by 2030, say researchers at the MRC Biostatistics Unit, University of Cambridge, and Public Health England (PHE).

24 Sep 2021

Johns Hopkins Medicine mathematical model to play major role in ending HIV nationwide

A new Johns Hopkins Medicine mathematical model to predict how the human immunodeficiency virus (HIV) spreads in urban areas will play a major role in a federal initiative aiming to reduce the incidence of HIV infections in the United States by 90% between 2020 and 2030.

24 Sep 2021

Investigational vaccine does not provide sufficient protection against HIV infection

An investigational HIV vaccine tested in the "Imbokodo" clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries.

31 Aug 2021

Certain high priority groups more likely to stop taking HIV prevention treatment, study finds

A large, detailed look at patients taking HIV-prevention drug therapy finds strong adherence soon after patients get the prescription, but less consistent use thereafter, particularly among groups considered high priority for receiving the medication.

27 Aug 2021

Study finds worsening disparities among states in use of HIV-prevention drugs

States with low initial use of HIV-prevention drugs are continuing to fall behind in usage among people at risk for the disease, a new study finds.

12 Aug 2021

Report highlights global shortfalls to end HIV infections among children and young women

In the final report from the Start Free, Stay Free, AIDS Free initiative, UNAIDS and partners warn that progress towards ending AIDS among children, adolescents and young women has stalled and none of the targets for 2020 were met.

23 Jul 2021

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.

15 Jul 2021

Deep learning could transform the ability to accurately interpret HIV test results

Pioneering technology developed by UCL and Africa Health Research Institute researchers could transform the ability to accurately interpret HIV test results, particularly in low- and middle-income countries.

18 Jun 2021

Elimination of HIV transmission by 2030 might be within reach among MSM in England

The annual number of new HIV infections among men who have sex with men (MSM) in England is likely to have fallen dramatically, from 2,770 in 2013 to 854 in 2018, showing elimination of HIV transmission by 2030 to be within reach - suggests work by researchers from the MRC Biostatistics Unit at the University of Cambridge and Public Health England (PHE), published in The Lancet HIV.

10 Jun 2021

Clinical trial investigates effectiveness of delivering HIV, substance use care through mobile clinics

A clinical trial is underway in five U.S. cities to determine whether delivering integrated health services through mobile clinics can improve HIV and substance use outcomes among people with opioid use disorder who inject drugs.

9 Jun 2021

Experimental monoclonal antibody could be a new weapon against HIV epidemic

An experimental, lab-made antibody can completely prevent nonhuman primates from being infected with the monkey form of HIV, new research published in Nature Communications shows.

7 Jun 2021

Centivax and US Naval Medical Research Center to begin Phase I clinical trial of antibody therapeutics

Centivax Inc. announced today that it has entered into a strategic partnership with the U.S. Naval Medical Research Center (NMRC) for Phase I clinical development of Centi-B9, Centivax's SARS-CoV-2 broad-spectrum injectable antibody therapeutic and prophylactic.

3 Jun 2021

New study aims to reduce HIV incidence among transgender women

HIV prevention services will be combined with access to gender-affirming hormonal therapy and peer health navigation to try to reduce the disproportionate percentage of transgender women who are HIV positive in an innovative study led by researchers at The University of Texas Health Science Center at Houston (UTHeath).

22 May 2021

Special issue of JANAC summarizes 40 years of nursing science throughout the HIV epidemic

From the very beginning of the AIDS epidemic in 1981, nurses have been at the forefront of patient care, advocacy, and research.

5 May 2021